(Q36150789)

12 August 2017

1 reference

title

Leflunomide: long-term clinical experience and new uses (English)

1 reference

12 August 2017

1 reference

ChEBI release 2020-05-28

J Peter Kaltwasser

1

1 reference

12 August 2017

Frank Behrens

series ordinal

2

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

Expert Opinion on Pharmacotherapy

12 August 2017

published in

1 reference

12 August 2017

volume

6

1 reference

12 August 2017

issue

5

1 reference

12 August 2017

page(s)

787-801

1 reference

Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.787

A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.787

The epidemiology of drug treatment failure in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.787

Considerations with the use of biological therapy in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.787

How does leflunomide modulate the immune response in rheumatoid arthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.787

Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.787

Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.787

Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.787

Anti-inflammatory effects of leflunomide on cultured synovial macrophages from patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.787

Clinical pharmacokinetics of leflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.787

Leflunomide: a review of its use in active rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.787

Leflunomide use during the first 33 months after food and drug administration approval: experience with a national cohort of 3,325 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.787

Dose escalation of leflunomide (LEF) to 40 mg once daily in patients with rheumatoid arthritis and insufficient response to standard dose LEF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.787

Leflunomide for the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.787

Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.787

A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.787

Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.787

Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.787

Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.787

Long term evaluation of radiographic disease progression in a subset of patients with rheumatoid arthritis treated with leflunomide beyond 2 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.787

The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.787

When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.787

The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.787

Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.787

Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.787

Treatment of severe psoriasis and psoriatic arthritis with leflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.787

Leflunomide in the treatment of psoriasis: results of a phase II open trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.787

Leflunomide in psoriasis and psoriatic arthritis: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.787

Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.787

Six months open label trial of leflunomide in active ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.787

Maintenance of remission with leflunomide in Wegener's granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.787

Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.787

Leflunomide treatment of Crohn's disease patients intolerant to standard immunomodulator therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.787

Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.787

Methotrexate and histologic hepatic abnormalities: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.787

Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.787

Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.787

Interstitial lung disease associated with leflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.787

21 January 2018

Identifiers

DOI

10.1517/14656566.6.5.787

1 reference

12 August 2017

1 reference